Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
- 18 December 2024 - 1 mins read
The purpose of the protocol is to determine safety, tolerability, recommended dose (RD), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of IPN60090 as a single agent (Part A) and in combination with pembrolizumab (Part B) or paclitaxel (Part C) in patients with advanced solid tumours and to evaluate food effect (Part D).
18 December 2024
1 mins read
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
18 December 2024
1 mins read
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
18 December 2024
1 mins read
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
18 December 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
18 December 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Follow-on Study
18 December 2024
1 mins read
Dysport® Pediatric Lower Limb Spasticity Study
18 December 2024
1 mins read
Dysport® Adult Lower Limb Spasticity Study
18 December 2024
1 mins read
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
18 December 2024
1 mins read
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
18 December 2024
1 mins read